Ownership and insider activity for Capricor Therapeutics, Inc. (CAPR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
Price
| Price | $8.56 |
| Market Cap | $492M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-25 | Krasney Karen | M-Exempt | 24,100 | $77K |
| 2026-06-25 | Krasney Karen | M-Exempt | 24,100 | $77K |
| 2026-06-25 | Krasney Karen | S-Sale | 24,100 | $732K |
| 2026-06-25 | Bergmann Anthony | M-Exempt | 24,100 | $77K |
| 2026-06-25 | Bergmann Anthony | M-Exempt | 24,100 | $77K |
| 2026-06-25 | Bergmann Anthony | S-Sale | 24,100 | $732K |
| 2026-06-22 | Krasney Karen | M-Exempt | 500 | $2K |
| 2026-06-24 | Krasney Karen | M-Exempt | 400 | $1K |
| 2026-06-22 | Krasney Karen | M-Exempt | 500 | $2K |
| 2026-06-24 | Krasney Karen | M-Exempt | 400 | $1K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.2M | $6.1M | $4.3M | $3.9M | $32.7M | $34.9M | $9.6M | $14.7M | $11.3M | $287.8M |
| Short-term Investments | $13.0M | $8.0M | $3.0M | $6.0M | 0 | 0 | $31.8M | $24.8M | $140.2M | $30.3M |
| Receivables | $223335 | $344575 | $204868 | $87968 | $56000 | $391750 | $547580 | $10.4M | $10.4M | $59167 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $18.1M | $15.7M | $8.5M | $10.5M | $33.7M | $36.4M | $42.9M | $50.9M | $163.4M | $322.9M |
| Property, Plant & Equipment | $435336 | $372096 | $574206 | $442806 | $850847 | $4.6M | $6.9M | $7.6M | $6.9M | $18.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $142253 | $93048 | $204868 | $6495 | $2165 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $18.7M | $16.3M | $9.2M | $11.1M | $34.6M | $41.3M | $50.1M | $58.7M | $170.5M | $355.9M |
| Accounts Payable | $3.0M | $1.7M | $1.3M | $897992 | $2.7M | $3.7M | $4.8M | $6.2M | $3.3M | $1.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | $246689 | $417632 | $682039 | $749112 | $834799 | $3.6M |
| Total Current Liabilities | $4.9M | $1.7M | $1.3M | $897992 | $3.0M | $4.1M | $23.6M | $31.3M | $21.0M | $35.8M |
| Long-term Debt | $17.0M | $3.4M | $3.4M | $3.4M | $3.4M | $3.4M | $3.4M | $3.4M | $3.4M | 0 |
| Total Liabilities | $22.8M | $5.0M | $4.6M | $4.3M | $6.4M | $10.0M | $38.3M | $36.1M | $25.0M | $50.2M |
| Retained Earnings | -$54.0M | -$51.5M | -$66.7M | -$74.4M | -$88.0M | -$108.1M | -$137.1M | -$159.4M | -$199.8M | -$304.9M |
| Total Equity | -$4.0M | $11.2M | $4.6M | $6.8M | $28.2M | $31.4M | $11.8M | $22.6M | $145.5M | $305.8M |
| Total Debt | $17.0M | $3.4M | $3.4M | $3.4M | $3.7M | $6.2M | $5.9M | $5.6M | $4.8M | $17.9M |
| Net Debt | $810969 | -$10.7M | -$3.9M | -$6.5M | -$29.0M | -$28.6M | -$35.5M | -$33.9M | -$146.7M | -$300.2M |
| Working Capital | $13.2M | $14.0M | $7.2M | $9.6M | $30.7M | $32.3M | $19.3M | $19.6M | $142.4M | $287.1M |
Financial Health
| Debt / Equity | 0.37 |
| Current Ratio | 7.35 |
Profitability
| Return on Equity | -56.60% |
| Return on Invested Capital | -40.08% |
| Return on Assets | -35.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ALLO · ARCT · CABA · EDIT · IMMP · LXEO
Explore sector: Healthcare · Biotechnology
More sections of CAPR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks